SEC Filing Summary: Mast Therapeutics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mast Therapeutics, Inc. on April 10, 2017, reporting events occurring on April 7, 2017. The filing concerns the Company's proposed business combination (Merger) with Savara Inc. and the associated transfer of its common stock listing from the NYSE MKT to The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Listing Transfer: The Board authorized the transfer of the Company's common stock listing from the NYSE MKT to Nasdaq in connection with the Merger.
- Delisting Notice: Written notice was provided to the NYSE MKT on April 7, 2017, to voluntarily delist the stock effective the first trading day after the Merger closes.
- Ticker Symbol Change: The stock will trade under the symbol "MSTX" on the NYSE MKT until the Merger closes, then switch to "SVRA" on Nasdaq.
- Regulatory Waiver: Savara agreed to waive the requirement for the Company to submit a listing application to the NYSE MKT as a condition for the Merger closing.
Outlook, Risks, and Management Commentary
The Company has filed a registration statement on Form S-4 (including a proxy statement and prospectus) with the SEC, which was declared effective on March 15, 2017. Management urges investors to review these documents before making voting or investment decisions. The filing includes standard disclaimers that this communication does not constitute an offer to sell securities and that no offering will be made except via a prospectus meeting Section 10 requirements of the Securities Act of 1933.
Investor Verification Checklist
- Verify the status of the Merger with Savara Inc. and the expected closing date.
- Review the Form S-4 proxy statement/prospectus for details on the transaction terms and director interests.
- Confirm the exact date the ticker symbol changes from "MSTX" to "SVRA" on Nasdaq.
- Check for any subsequent filings regarding the completion of the NYSE MKT delisting.